Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JGPMA Proposes “Drug Benefit Standard Price” System
June 25, 2007
- Pfizer Most Active in GP Market: MOSS Survey
June 25, 2007
- GENERIC NEWS IN BRIEF
June 25, 2007
- BUSINESS NEWS IN BRIEF
June 25, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 25, 2007
- NEW PRODUCTS
June 25, 2007
- Hemorrhoid Recurrence Rate 16% 1 Year after Zione Treatment
June 25, 2007
- Monthly Pay Raise Averages \6,627 for 8 Pharma Companies
June 18, 2007
- Consensus Not Reached on the Need for Practical Experience: Exam for Drug Salespersons
June 18, 2007
- Diovan Recaptures Top Position in April
June 18, 2007
- Acute Stage Rehabilitation Important: Korosho
June 18, 2007
- BUSINESS NEWS IN BRIEF
June 18, 2007
- Arixtra Should Promote Awareness of VTE: GSK
June 18, 2007
- Mr Sawai Responds to Criticisms
June 18, 2007
- JPA Concerned about Excess of Pharmacists
June 18, 2007
- GENERIC NEWS IN BRIEF
June 18, 2007
- WG Inaugurated to Predict Demand & Supply for Pharmacists
June 18, 2007
- 28 Drugs (13 APIs) Included in NHI Price List
June 18, 2007
- Sales of 23 TSE Section 1 Companies Up 2.2%
June 18, 2007
- 77 Applications for New Drugs Approved in FY2006: PMDA
June 18, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…